Abstract: Innovation-driven to help fight COVID-19
Recently, at the 29th Annual Conference and Awards Ceremony of the BioNJ biomedical alliance (BioNJ) held in New Jersey, Fosun Diagnostics' self-developed COVID-19 Nucleic Acid Detection Kit (COVID-19 RT-PCR Detection Kit) won the "Innovation Award for Fighting covid-19". In its comments, sponsor BioNJ said the award was given to member companies with an impact on the fight against COVID-19 in the United States and around the world in recognition of innovation, collaboration and dedication.
BioNJ is the New Jersey Life Sciences Industry Association with nearly 400 member companies and has represented research life sciences organizations and stakeholders in the healthcare ecosystem from early start-ups to large biopharmaceutical companies for nearly 30 years.
Photo: Fosun Diagnostics awarded the "Covid-19 Innovation Award" by BioNJ in the United States
As one of the earliest manufacturers in China to carry out the research and development of novel coronavirus diagnostic reagents and obtain the national emergency approval of the State Food and Drug Administration, Fosun Diagnostics' novel coronavirus (2019-nCoV) nucleic acid detection kit (fluorescent PCR method) is the first product in the industry to submit a complete clinical application data report. The reagent has been obtained NMPA, CE, FDA EUA, WHO EUL and TGA and other certificates, the product is suitable for the new crown virus nucleic acid detection of the same person, to the greatest extent to avoid the unpredictable public health impact caused by missed tests, false detection, and reduce the consumption of manpower and material resources caused by repeated testing in the laboratory.
On April 13, 2022, with the official approval of Fosun Diagnostics' Covid-19 Antigen CARD Kit, Fosun Diagnostics has become one of the dual-certificate companies that have obtained both the registration certificate of new coronavirus nucleic acid and antigen reagents.
At present, Fosun Diagnostics' new coronavirus antigen self-test kit has obtained the EU CE certificate, and has completed the German BfArM registration, and has been included in the EU Health and Safety Commission HSC Common List (EU Common White List), which can be sold and used in 27 EU countries and countries that recognize EU CE certification.
At the same time, Fosun Diagnostics can provide a complete set of reagents, equipment, consumables and other overall solutions for new crown nucleic acid detection, which has been comprehensively verified for performance, with high sensitivity, high flexibility, high reliability and other advantages, and has been applied in many provincial and municipal tertiary hospitals in China, and has been widely praised. The Songjiang Cabin Laboratory, undertaken by Shanghai Bohao Inspection, a wholly-owned subsidiary of Fosun Diagnostics, also adopted the scheme, which took only 48 hours from the determination of the plan to the opening of the cabin, and the plan was strictly reviewed and passed by the Shanghai Municipal Clinical Inspection Center, health supervision and other departments, helping Shanghai overcome the epidemic at the most difficult moment.
【Subtitle】Adhering to domestic independent research and development, Fosun Diagnostics continues to help the global fight against the new crown epidemic
At the beginning of the outbreak of the new crown epidemic in early 2020, Fosun Diagnostics closely followed the epidemic situation and urgently carried out the research and development of new coronavirus diagnostic reagents, while helping the domestic epidemic prevention and control work, the 2019-nCOV nucleic acid detection kit was also exported to more than 10 countries around the world, including Portugal, Hungary, Belgium, France, Germany and so on, and the "Made in Shanghai" brand effectively supported the global anti-epidemic action with strength and speed.
In recent years, Fosun Diagnostics has successively undertaken the "Science and Technology Support Plan" of the Ministry of Science and Technology, the national "863 Plan" and the "13th Five-Year Plan" National Science and Technology Major Special Projects, etc. At the 2021 Zhejiang Provincial Science and Technology Award Conference, the new coronavirus (2019-nCoV) nucleic acid detection kit (fluorescence PCR method) developed by Fosun Diagnostics was awarded the "First Prize of the 2020 Zhejiang Science and Technology Progress Award" as the result of the "Research on Key Technologies for the Prevention and Control of Novel Coronavirus Pneumonia". This achievement also won the "Second Prize of the 2020 Shanghai Science and Technology Progress Award".
This overseas award is an affirmation of Fosun Diagnostics' active participation in the global anti-epidemic action by making full use of its accumulated product research and development capabilities and international experience for many years. In the future, Fosun Diagnostics will work with all parties to further broaden the overseas application scenarios of Fosun Diagnostics' COVID-19 testing products, enhance the competitiveness of enterprises' COVID-19 testing products in the international market, and continue to contribute to the global epidemic prevention and control work.